Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Michele B. Kaufman, PharmD, BCGP

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer and editor. She is also a pharmacist at New York Presbyterian Hospital–Lower Manhattan campus. She has been a past guest lecturer at Touro College of Pharmacy in New York City for the Medical Writing elective. Dr Kaufman is a member of the New York City Society of Health-Systems Pharmacy, the New York State Council of Health-System Pharmacists, the Academy of Managed Care Pharmacy (AMCP)—Northeast Region Affiliate Chapter, the American Society of Consultant Pharmacists and the Empire State-Metropolitan NY Chapter of the American Medical Writers Association. She received her BS in Pharmacy from the University of Rhode Island (URI) College of Pharmacy and her Doctor of Pharmacy degree from Massachusetts College of Pharmacy and Allied Health Sciences in Boston. She also completed a Drug Information Fellowship at the URI Drug Information Center/Roger Williams Medical Center in Providence, R.I. Dr Kaufman is a registered pharmacist and is a Board-Certified Geriatric Pharmacist.

Articles by Michele B. Kaufman, PharmD, BCGP

FDA Advisory Committee Votes in Favor of Romosozumab Approval

Michele B. Kaufman, PharmD, BCGP  |  January 30, 2019

An FDA advisory committee voted 18-1 in favor of approving romosozumab to treat postmenopausal women with osteoporosis.

FDA Update: Priority Review for Non-Opioid Treatment & New Warning for Fluoroquinolones

Michele B. Kaufman, PharmD, BCGP  |  January 23, 2019

The FDA has granted priority review to a non-opioid, postoperative pain treatment, HTX-011…

Results of SPIRIT: A Head-to-Head Trial of Ixekizumab vs. Adalimumab in Active PsA

Michele B. Kaufman, PharmD, BCGP  |  January 14, 2019

In a recent study, ixekizumab proved safe and effective in treating adults with psoriatic arthritis (PsA) and plaque psoriasis compared with adalimumab…

FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  January 7, 2019

The FDA has approved Truxima (rituximab-abbs), which is biosimilar to Rituxan (rituximab), for treating adults with CD20-positive, B-cell non-Hodgkin’s lymphoma…

Can IL-6 Predict Sarilumab Response?

Michele B. Kaufman, PharmD, BCGP  |  January 2, 2019

Recent post-hoc analyses of two Phase 3 clinical trials show that RA patients with high interleukin 6 levels taking sarilumab experienced improved symptoms and less joint damage than those using other treatments…

Bimekizumab Promising for PsA

Michele B. Kaufman, PharmD, BCGP  |  December 18, 2018

CHICAGO—Bimekizumab is an investigational interleukin (IL) 17A and IL-17 neutralizing agent being studied to modulate inflammation in psoriasis, psoriatic arthritis and ankylosing spondylitis. During the late-breaking abstract session at the 2018 ACR/ARHP Annual Meeting, researchers reported on the results of a 48-week, Phase 2b, randomized, double-blind, placebo-controlled study of bimekizumab in patients with active psoriatic…

Long-Term Data Show Baricitinib Is Safe & Effective for RA

Michele B. Kaufman, PharmD, BCGP  |  December 17, 2018

Data from multiple clinical trials and an extension study showed baricitinib is safe and effective for the long-term treatment of adults with RA…

Upadacitinib Monotherapy Proves Promising; Plus FDA Approves Tocilizumab Autoinjector

Michele B. Kaufman, PharmD, BCGP  |  December 10, 2018

In a study, RA patients taking upadactinib monotherapy experienced less pain and morning joint stiffness than methotrexate-treated patients…

FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Receive FDA Priority Review

Michele B. Kaufman, PharmD, BCGP  |  December 3, 2018

The FDA has approved halobetasol propionate lotion as a topical treatment for plaque psoriasis…

Rituximab Receives Label Update for ANCA-Associated Vasculitis

Michele B. Kaufman, PharmD, BCGP  |  November 26, 2018

The FDA has approved an update for rituximab’s label, which will include safety and efficacy information for treating ANCA-associated vasculitis…

  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 45
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences